Revolutionizing Lobular Breast Cancer Research with New National Consortium in the U.S.

A New Era for Lobular Breast Cancer Research in the U.S.

In a groundbreaking move, the Lobular American Research Consortium (LARC) has been initiated, marking the first coordinated national effort dedicated entirely to invasive lobular breast cancer (ILC). More than 20% of breast cancer patients are diagnosed with ILC, yet less than 1% of the research funding has historically been allocated to this type. The launch of LARC, supported by a significant $250,000 catalytic seed funding from The Dynami Foundation, aims to bridge this gap and accelerate critical research aimed at understanding and treating lobular breast cancer more effectively.

A Collaborative Approach to Research

LARC is an independent, investigator-led scientific consortium that unites leading researchers and academic cancer centers across the U.S. and Canada, enabling high-level collaboration amongst scientists dedicated to exploring the complexities of lobular breast cancer. This cross-institutional collaboration will facilitate data sharing and the advancement of various research areas including lobular biology, cancer detection, and patient outcomes. The consortium is focused on developing infrastructure necessary to support early-stage initiatives, providing a robust framework for collaborative research.

Leadership and Strategic Vision

The scientific leadership of LARC is composed of a prestigious panel of clinicians and researchers who are well-known within the field of lobular breast cancer. With co-chairs Rachel Jankowitz from the University of Pennsylvania and Matthew J. Sikora from the University of Colorado Anschutz, the consortium's executive committee further includes experienced professionals from esteemed institutions such as the University of Texas Southwestern, University of California San Francisco, and Memorial Sloan Kettering Cancer Center.

Flora Migyanka, Founder of The Dynami Foundation and a long-term survivor of lobular breast cancer, serves as both the Founding Philanthropic Partner and Patient Champion for LARC. Her commitment to fostering research in this neglected field showcases the dedication needed to drive meaningful change in ILC research.

Bridging Research Gaps

Despite the rising incidence of ILC, funding for dedicated research remains insufficient. The launch of LARC is signaling a crucial shift in addressing these pressing issues, highlighting the unique biological characteristics of lobular breast cancer that necessitate specific research approaches. According to Dr. Sikora, the establishment of LARC provides the much-needed collaborative infrastructure essential for fast-tracking discovery that ultimately improves patient outcomes.

Catalytic Support from The Dynami Foundation

The Dynami Foundation plays a critical role in supporting LARC, providing not only infrastructure but also the necessary coordination and funding to launch collaborative research initiatives. This nonprofit organization is committed solely to furthering research and understanding of invasive lobular breast cancer. Flora Migyanka's leadership has been pivotal; through her extensive connections and efforts, she has successfully gathered leading investigators to partake in this critical endeavor.

Migyanka emphasizes that patients facing lobular breast cancer cannot afford to wait longer for scientific advancements. The unique structure of LARC, allowing for independent scientific leadership while benefiting from a philanthropic platform, aims to catalyze research developments that directly benefit patients.

Looking Ahead: A Call for Collaboration

Moving forward, LARC is poised to enhance its impact through a series of scientific meetings starting in 2026. The inaugural gathering is set to take place in September 2026, just before the International Lobular Breast Cancer Symposium, enriching the discussions about research priorities and new collaborative initiatives. The consortium is actively inviting organizations and individuals motivated to improve ILC outcomes to engage and collaborate.

LARC is set to revolutionize how lobular breast cancer research is conducted, making strides toward better understanding and treatment options for this prevalent yet often overlooked disease. As they embark on this critical journey, LARC and The Dynami Foundation are committed to building a future where ILC is prioritized in cancer research and treatment paradigms.